• 19 March 2015

    Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces today that it has published positive Phase 2b clinical data for its novel TrkA kinase inhibitor CT327 in Acta Dermato-Venereologica, one of the pre-eminent international peer-review journals in dermatology.

  • 5 February 2015

    InDex Pharmaceuticals today announced that the Board of Directors has named Peter Zerhouni as new CEO. Peter Zerhouni comes from a position as CEO at Diamyd Medical AB where he has been instrumental in bringing the company’s business and clinical trials forward. He will succeed Jesper Wiklund, who has led the company since 2011.

  • 3 February 2015

    InDex Pharmaceuticals today announced that results from COLLECT, a clinical study of the toll-like receptor 9 (TLR9) agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis, will be subject to an oral presentation at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO). The congress is to be held in Barcelona, Spain on February 18-21, 2015.

  • 28 January 2015

    JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of next generation transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, today announced the appointment of medical device veteran and JenaValve Chairman of the Board, Jan Keltjens, as Interim Chief Executive Officer and Executive Chairman. He replaces David J. Drachman, who has resigned from the company for non-business related personal reasons. Mr. Keltjens will assume the role effective immediately and until a permanent replacement for Mr. Drachman has been hired. 

  • 15 January 2015

    Arsanis, Inc. scientists and their collaborators at Adimab, LLC have described a unique monoclonal antibody with the potential to treat Staphylococcus aureus (S. aureus) infections through the simultaneous neutralization of multiple key toxins produced by S. aureus, including alpha-hemolysin and four additional leukocidins. The findings are published online this week in the journal mAb and demonstrate superior in vitro potency compared to antibodies targeting alpha-hemolysin alone. The mAb also shows high protective efficacy from lethal S. aureus infections in several animal models.